Antibody Drug Conjugates Market: Riding on the Growth Wave

While there are close to 200 ADCs in various stages of development, the market field is currently going through a gradual transition, shifting from relying on conventional technologies to newer approaches for generating ADCs. The Antibody Drug Conjugates Market (4th Edition), 2017-2030 report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion on the future potential of this evolving market.  Some of the most interesting insights from our study are presented below.

A Mushrooming Area For Researchers, Ready For Strong Commercial Growth
With more than 10,000 patents filed in the last decade alone, the ADC market continues to garner significant interest within the biopharmaceutical industry.

The Promising Clinical Pipeline Offers A Variety Of Novel Opportunities

The pipeline, featuring product candidates that target various antigens with different warheads, is anticipated to present several opportunities in the near future

As per Roots Analysis, close to 55% of the antibody drug conjugates are currently in phase I of the clinical pipeline and around 5% have been approved and commercially available in market

Well-Known Players Have Steadily Driven Innovation

Innovation in this domain is presently focused on exploring different targets, more potent payloads and stable linkers to tap opportunities across various oncological indications.

Specifically, Novel Conjugation Approaches Have Recently Surfaced

Several novel conjugation approaches have also been developed and implemented to enhance the stability and therapeutic indices of ADC molecules.

Extensive Clinical Research, Offering Valuable Data Insights, Continues To Hold The Key

Ongoing improvements in clinical research have revealed better insights on dosing and enabled more efficient MTD estimations.

Led by KOLs from Across the Globe, We Believe The Promise Will Evolve Significantly

The field has evolved under the guidance of several researchers who have emerged as key opinion leaders.

Venture Capital Funding, As Before, Will Be One Of The Primary Enablers

Well funded start-ups are actively contributing to drug development efforts while the more established players continue to enhance their offerings through partnerships

Various stakeholders are continuously investing in antibody drug conjugates market. In  past few years over 100 funding instances have been recorded in this field reflecting the growing interest of players

The Market’s Rapid Growth, Both In The Short-Term And Long-Term…

Post the approval and launch of multiple late-phase product candidates, the market is expected to grow at a rapid pace.

… Will Be Driven by Rapid Ongoing Advances

Advances in payload and linker technologies are likely to result in better opportunities in the long term as more drugs get commercialized for a diverse range of indications

The ADC therapeutics market is fragmented across different segmentations including type of payload, type of linkers, indication and geography. By 2035, ADC conjugates will be majorly used for the treatment of breast cancer

Several Stakeholders, Including CMOs, Will Benefit From The Impending Growth Wave

Well funded start-ups are actively contributing to Antibody Drug development efforts while the more established players continue to enhance their offerings through partnerships.

To know more please click Antibody Drug Conjugates Market (4th Edition), 2017-2030 For any queries / suggestions or if you’d like to get access to the full research results, please do not hesitate to contact us at